Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

NCT01980654 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
B-cell Lymphoma
Non-Hodgkin's Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: rituximab

Sponsor

Pharmacyclics LLC.